675 related articles for article (PubMed ID: 20622899)
1. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
2. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
4. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
[TBL] [Abstract][Full Text] [Related]
5. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
[TBL] [Abstract][Full Text] [Related]
6. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
[TBL] [Abstract][Full Text] [Related]
7. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response.
Ayllón V; O'connor R
Oncogene; 2007 May; 26(24):3451-61. PubMed ID: 17160018
[TBL] [Abstract][Full Text] [Related]
8. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.
Zeng PY; Berger SL
Cancer Res; 2006 Nov; 66(22):10701-8. PubMed ID: 17108107
[TBL] [Abstract][Full Text] [Related]
9. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
[TBL] [Abstract][Full Text] [Related]
10. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
[TBL] [Abstract][Full Text] [Related]
11. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
Park JH; Lin ML; Nishidate T; Nakamura Y; Katagiri T
Cancer Res; 2006 Sep; 66(18):9186-95. PubMed ID: 16982762
[TBL] [Abstract][Full Text] [Related]
12. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.
Lei B; Liu S; Qi W; Zhao Y; Li Y; Lin N; Xu X; Zhi C; Mei J; Yan Z; Wan L; Shen H
Histopathology; 2013 Nov; 63(5):696-703. PubMed ID: 24025073
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
[TBL] [Abstract][Full Text] [Related]
14. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q
Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458
[TBL] [Abstract][Full Text] [Related]
15. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma.
Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Anticancer Res; 2016 Dec; 36(12):6457-6466. PubMed ID: 27919968
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase.
Chai Y; Xue H; Wu Y; Du X; Zhang Z; Zhang Y; Zhang L; Zhang S; Zhang Z; Xue Z
Exp Ther Med; 2018 Jun; 15(6):4822-4828. PubMed ID: 29805502
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53.
Nandi AK; Ford T; Fleksher D; Neuman B; Rapoport AP
Biochem Biophys Res Commun; 2007 Jun; 358(1):181-8. PubMed ID: 17482142
[TBL] [Abstract][Full Text] [Related]
19. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.
Zhu F; Zykova TA; Kang BS; Wang Z; Ebeling MC; Abe Y; Ma WY; Bode AM; Dong Z
Gastroenterology; 2007 Jul; 133(1):219-31. PubMed ID: 17631144
[TBL] [Abstract][Full Text] [Related]
20. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
